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During apoptosis nuclear morphology changes dramatically due to alterations of chromatin
architecture and cleavage of structural nuclear proteins. To characterize early events in
apoptotic nuclear dismantling we have performed a proteomic study of apoptotic nuclei. To
this end we have combined a cell-free apoptosis system with a proteomic platform based on
the differential isotopic labeling of primary amines with N-nicotinoyloxy-succinimide. We
exploited the ability of this system to produce nuclei arrested at different stages of apoptosis
to analyze proteome alterations which occur prior to or at a low level of caspase activation.
We show that the majority of proteins affected at the onset of apoptosis are involved in
chromatin architecture and RNA metabolism. Among them is DEK, an architectural chro-
matin protein which is linked to autoimmune disorders. The proteomic analysis points to
the occurrence of multiple PTMs in early apoptotic nuclei. This is confirmed by showing
that the level of phosphorylation of DEK is decreased following apoptosis induction. These
results suggest the unexpected existence of an early crosstalk between cytoplasm and
nucleus during apoptosis. They further establish a previously unrecognized link between
DEK and cell death, which will prove useful in the elucidation of the physiological function
of this protein.
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1 Introduction
The demolition of the nucleus during apoptosis proceeds in
distinct steps and through different shapes beginning with a
more or less pronounced peripheral chromatin margination,
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often accompanied by disruption of the nucleolus, to a late
morphology characterized by shrinkage, convolution of the
nuclear envelope, and fragmentation into apoptotic bodies
[1, 2]. These structural changes are mainly the consequence
of the proteolysis of nuclear proteins like lamins and Tpr, and
of chromatin cleavage into high-molecular weight and oligo-
nucleosomal fragments [3–6]. The major execution system
involved in these processes is the caspase family of proteases
[7]. These enzymes can directly cleave nuclear proteins and
activate apopototic DNases like caspase-activated DNase
(CAD)/DNA fragmentation factor (DFF40). In addition, sev-
eral caspase-independent factors were shown to contribute to
apoptotic nuclear alterations, including AIF [8], endonu-
clease G [9], DNaseII [10], phospholipase A2 [11], and Acinus
[12].
Abnormalities in the packaging of nuclear constituents
into apoptotic bodies and their subsequent clearance by
phagocytosing cells may lead to the exposure of novel anti-
gens and the initiation of an autoimmune response. Indeed,
circulating antinuclear autoantibodies are a hallmark of
many systemic autoimmune disorders [13, 14]. Apoptosis-
induced PTMs of nuclear proteins may increment the
immunogenicity of self-antigens [15]. Therefore, the study of
apoptosis-induced structural and functional alterations of
nuclear proteins is of crucial importance to understand the
mechanisms regulating apoptotic nuclear dismantling and
its connection to autoimmunity.
The technique of choice to achieve a comprehensive
characterization of changes in the protein complement of the
nucleus during apoptosis is subcellular proteomics [16]. This
strategy usually consists of a combination of cell fractiona-
tion procedures and comparative proteomic analysis of the
compartment of interest, in this case purified nuclei. The
main advantage of this approach is the enrichment of low-
abundance proteins which may remain undetected when
total crude extract is employed as starting material, mainly
due to the limited resolving capacity of 2-DE [17].
Subcellular proteomic studies of apoptosis are still sparse
so far. Two groups have reported on the translocation of
hnRNP proteins out of the nucleus during cell death [18, 19]
and characterized apoptosis-induced alterations of the
nuclear matrix [20]. They both employed the classical
approach of comparative high-resolution 2-DE of nuclear
fractions followed by the mass spectrometric analysis of
interesting spots. The range of pI that was analyzed extended
from approximately 5 to 9 in one case [18], and from 4 to 7.5
in another case [20]. However, a large number of nuclear
proteins, in particular those directly binding to DNA, are
positively charged and migrate at pI values .10. Such pro-
teins are difficult to identify by conventional approaches due
to the poor resolution and reproducibility of 2-Dgels in the
basic region [21].
In this work we have employed an alternative strategy to
perform a proteomic study of apoptotic nuclei. We exploited
a recently developed technique of stable isotopic labeling of
protein mixtures, termed ICPL (isotope coded protein
label), which was successfully employed for the analysis of
basic proteins [22]. Similarly to the isotope coded affinity tag
(ICAT) platform pioneered by Aebersold and coworkers [23],
the protein samples to be compared are chemically deriva-
tized with two distinguishable isotopic forms (light, non-
deuterated, d0 and heavy, deuterated, d4) of the ICPL
reagent, N-nicotinoyloxy-succinimide [22]. The differentially
labeled samples are subsequently combined and separated
by high-resolution 2-DE. Here, proteins labeled with iso-
topically different forms of the ICPL reagent coseparate and
are recovered from the same spot. Changes in protein
abundances are then accurately determined by comparing
the ratio of the mass spectrometric signal intensities of the
heavy and light forms of the labeled peptides. Differently
from the ICAT reagent, which labels cysteines, the ICPL
reagent quantitatively modifies primary amino groups. This
reduces the pI of the labeled proteins and shifts the position
of the corresponding spots in 2-DE to the acidic side. The
magnitude of the shift is proportional to the number of
basic amino groups present. Highly basic proteins, such as
nuclear proteins, can thus be separated in the neutral to
acidic region of the gels, where resolution is not a problem
[22].
Cell-free apoptosis systems have been instrumental to
the identification of many factors involved in apoptotic
nuclear execution [24]. Typically, these systems consist of
nuclei purified from healthy cells or tissues and cytosolic
extracts derived from cells stimulated to undergo apoptosis
[25–27]. One advantage of this approach is that apoptotic
alterations are induced in all nuclei independently of the
variable responsiveness of individual cells to the apoptotic
trigger. The stage of apoptosis reached in these nuclei
depends on the time point at which the cells are harvested
for extract isolation after apoptosis induction. The process
of nuclear destruction can thus be temporally dissected. In
particular, this method allows for the study of early apop-
totic events which are difficult to observe in a cell popula-
tion due to the asynchronous onset of the apoptotic pro-
cess.
Goal of this study was the identification of early altera-
tions of the nuclear proteome, which may occur prior, or at
the beginning of the caspase cascade. To this end we have
exploited cell-free apoptosis as a technique to generate early
apoptotic nuclei and performed a comparative proteomic
study using the ICPL platform.
Our results show that already prior to detectable altera-
tions of chromatin structure and preceding the full activation
of executioner caspases a number of nuclear proteins are
altered in death receptor-induced cell death. The majority of
the identified proteins participate in chromatin function and
RNA metabolism. Among them is DEK, an architectural
chromatin factor that has been implicated in the pathogen-
esis of cancer and autoimmune disorders [28, 29]. The
involvement of DNA and RNA-binding factors in the early
phase of apoptosis is a previously unrecognized aspect of the
receptor mediated death pathway.
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2 Materials and methods
2.1 Cell culture, apoptosis induction, and
measurement of caspase activity
Jurkat T-cells (Clone E6–1) were grown in RPMI 1640 medi-
um containing 5% FCS at 377C in a humidified atmosphere.
For induction of apoptosis cells were incubated in serum-free
medium at a density of 56106 cells/mL with 2.5% CD95
ligand (CD95-L)-containing culture supernatant from CD95-
L-expressing N2A cells [30]. Apoptosis in the culture was
monitored at regular intervals by staining aliquots of the cells
with a combination of the fluorescent chromatin dyes
Hoechst 33342 (500 ng/mL) and Sytox (500 mM). Cells
impermeable to Sytox and with condensed or fragmented
nuclei were scored as apoptotic.
Caspase activity was determined essentially as described
previously [4]. Briefly, cells were lysed in 25 mM HEPES
pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.5% Triton X-100 and
the cleavage of DEVD-afc (40 mM) was monitored fluorime-
trically in reaction buffer (50 mM HEPES pH 7.5, 10 mM
DTT, 1% sucrose, 0.1% CHAPS) over a period of 20 min at
377C with lex = 390 nm and lem = 505 nm. The activity was
calibrated using afc standard solutions. Measurements were
run in triplicate.
2.2 Isolation of cytosolic extracts
Cells were harvested by centrifugation at 47C, washed twice
carefully in ice-cold PBS and once in transport buffer
(20 mM HEPES, pH 7.3, 110 mM potassium acetate, 5 mM
sodium acetate, 2 mM magnesium acetate, 0.5 M EGTA,
250 mM sucrose) supplemented with protease inhibitors and
1 mM DTT. After addition of an amount of transport buffer
corresponding to the same volume of the packed cell pellet
containing 2.4 mg/mL digitonin (equivalent to 60 mg digito-
nin/56107 cells) the cells were lysed for 10 s under vigorous
stirring, followed by incubation on ice for 3 min. Organelles
and cell debris were removed by centrifugation at 18 0006g
for 15 min at 47C. The supernatant was snap frozen and
stored at 2807C.
2.3 Isolation of mouse liver nuclei
Isolation of nuclei was performed according to the protocol
of Blobel and Potter [31] with modifications introduced by
Cordes [32]. All separation steps were performed at 47C. All
buffers were supplemented with 1 mM DTT and 30 mg/mL
trypsin-inhibitor immediately before usage. Liver tissue of 2–
30 g from C3HeB/FeJ mice were homogenized in 50–100 mL
of ice-cold buffer A (15% sucrose, 1 mM Tris/HCl pH 7.2,
70 mM KCl, 2 mM MgCl2). The homogenate was filtered
through gaze and centrifuged for 10 min at 47C and 10006g.
The pellet was resuspended in buffer A and mixed with a
92% sucrose solution in 10 mM Tris/HCl pH 7.2 and 2 mM
MgCl2 to yield a 70% sucrose suspension that was finally
transferred on top of 72% sucrose cushions. Nuclei were
separated by centrifugation for 60 min at 47C and 40 0006g.
The pelleted nuclei were resuspended in an adequate volume
of buffer A, dounced and centrifuged again for 10 min at 47C
and 10006g. Nuclei were stored at 2807C in buffer A sup-
plemented with 20% glycerol.
2.4 Cell-free apoptosis reaction
Purified mouse liver nuclei (16108) were incubated with a
volume of cytosolic extract corresponding to 4 mg of total
protein in extract dilution buffer (10 mM HEPES pH 7.0,
50 mM NaCl, 2 mM MgCl2, 5 mM EGTA) in a total volume of
600 mL. The reactions were supplemented with an ATP
regenerating system (10 mM phosphocreatine, 2 mM ATP,
1 mM DTT, and 15–20 mU/mg creatine phosphokinase) and
incubated at 377C under moderate shaking (3006rpm) for
10 min. The nuclei were then recovered from the reaction
mixture by centrifugation through a small sucrose step gra-
dient consisting of 40 and 15% sucrose cushions (500 mL
each) in 10 mM Tris/HCl pH 7.2 for 2 min at 47C and
10 0006g.
2.5 Preparation of samples for immunoblot analysis
For the preparation of whole cell extracts, Jurkat cells were
harvested by centrifugation, washed in ice-cold PBS, resus-
pended in 957C lysis buffer (50 mM Tris/HCl pH 8.0, 0.5%
SDS, 1 mM DTT), and heated at 957C for 10 min. Cell debris
was removed by centrifugation at 20 0006g for 10 min.
Extracts for the analysis of cytochrome c release from
mitochondria were prepared by selective digitonin permea-
bilization of the plasma membrane as described by Single et
al. [33]. Briefly, 46106 cells were harvested and resuspended
in 250 mL PBS. Plasma membrane lysis was performed by
adding 250 mL of digitonin solution (130 mg/mL in 500 mM
sucrose) to the cell suspension under vigorous stirring on a
vortex for 10 s and further incubation at RT for 30 s. The
cytosolic fraction was quickly isolated by centrifugation for
60 s at 14 0006g and 47C. Proteins in the supernatant were
precipitated with 5% TCA at 2207C overnight.
For the analysis of nuclear proteins, nuclei recovered
from the cell-free reaction (see above) were lysed in 957C lysis
buffer (50 mM Tris/HCl pH 8.0. 0.5% SDS, 1 mM DTT).
2.6 Antibodies and immunoblot analysis
Whole cell extracts were employed for the detection of cas-
pase-8 and caspase-3 processing, and Bid cleavage. Mito-
chondrial cytochrome c release was analyzed in digitonin
lysates, and cleavage of PARP-1 and lamin B in nuclear
extracts.
Proteins were separated by SDS-PAGE according to
Laemmli [34], transferred to NC membranes (Amersham
Pharmacia Biotech, Uppsala, Sweden), blocked with 5%
nonfat dried milk in TBST (50 mM Tris/HCl pH 8.0, 0.05%
© 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
Proteomics 2006, 6, 5758–5772 Cell Biology 5761
Tween 20, 150 mM NaCl) for 1 h at RT and incubated with
primary antibodies specific for caspase-8 and caspase-3 (Cell
Signaling Technology, Danvers, MA, USA), cytochrome c
(Becton Dickinson Biosciences, Franklin Lakes, NJ, USA),
Bid (Biosource International, Camarillo, CA, USA), lamin B
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), and
PARP-1 (clone CII-10, kind gift of A. Buerkle) diluted in
TBST containing 5% nonfat dry milk for 1 h at RT. Filter
washings were in TBST alone. Incubations with HRP-cou-
pled secondary antibodies were in TBST-milk at room tem-
perature for 1 h. The Super Signal Western blotting detection
system (Pierce Biotechnology, Rockford, IL, USA) was used
according to the manufacturer’s instructions.
2.7 DNA fragmentation assay
Nuclei recovered from the cell-free apoptosis reaction (3–
56105) were dissolved in 200 mL DNA lysis buffer (100 mM
Tris/HCl pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl)
and incubated for 4 h at 377C with 100 mg/mL proteinase K.
After separation of insoluble material, the DNA was recov-
ered from the supernatant by isopropanol precipitation,
resuspended in TE buffer and treated with 1 mg/mL RNase
for 30 min at 377C. Oligonucleosomal DNA fragments were
separated by conventional 1% agarose gel electrophoresis
and visualized on a UV transilluminator after staining the
gel with SybrGreen (Molecular Probes, Eugene, OR, USA)
according to the manufacturer’s instructions.
2.8 ICPL reagent labeling and 2-DE
An equal number of nuclei recovered from control and
apoptotic cell-free reactions were dissolved in 6 M guani-
dine/HCl pH 8.5 by sonication and vigorous shaking. In-
soluble material was removed by centrifugation. The super-
natants were adjusted to the same protein concentration
(5 mg/mL) and labeled with the d0-(light, control) and d4-
(heavy, apoptosis) substituted isoforms of N-nicoti-
noylsuccinimide, respectively, as described in Schmidt et al.
[22]. Equal aliquots of the two samples were mixed and dia-
lyzed (cutoff 8 kDa) in a buffer containing 8 M urea, 2 M
thiourea, 4% CHAPS, and 40 mM DTT. Carrier ampholytes
pH 3–10 and Bromphenol blue were added to a final con-
centration of 2% (v/v) and 0.0075% (w/v). Samples were
applied to IPG strips with a linear separation range of
pH 3–6 (Amersham Biosciences). After overnight rehydra-
tion, IEF was carried out at 207C and 80 kVh in the follow-
ing steps: 1 h at 300 V followed by a 300 V increase every
15 min to 5000 V and 15 h at 5000 V. Strips were then
soaked for 2610 min in a buffer containing 50 mM Tris/
HCl, pH 8.8, 6 M urea, 30% w/v glycerol and 4% w/v SDS
and a trace of bromphenolblue. One percent w/v DTT was
added to the first, 4% (w/v) iodoacetamide was added to the
second equilibration step. Second dimension electrophore-
sis was performed with an Ettan Dalt II system (Amersham
Biosciences). IPG strips were placed on top of a 13% poly-
acrylamide gel and electrophoresis was carried out at 207C
for 1 h at a constant current of 5 mA per gel. The current
was then increased to 10 mA until the color front reached
the lower end of the gel. Gels were silver-stained and scan-
ned with a color image scanner (Sharp JX-330, Mahwah, NJ,
USA). Protein spots were excised with an automatic cutter
(BioRad, Munich, Germany) and enzymatically cleaved in-
gel with trypsin (0.05 mg) overnight at 307C. Protein frag-
ments were eluted with acidic and organic solvents and
vacuum dried as previously described [22].
2.9 MALDI-TOF/TOF analysis and data processing
Eluted peptides were redissolved in 3 mL 50% ACN and
0.2% TFA. 0.4 mL of this solution were mixed with the same
volume of matrix solution (CHCA, 2.5 mg/mL) on the
MALDI target. Mass spectra were acquired with a Proteom-
ics Analyzer 4700 (MALDI-TOF/TOF) mass spectrometer
(Applied Biosystems, Forster City, CA, USA). Mass analysis
was performed in the positive reflector mode with a deflec-
tion cut-off range corresponding to a mass/charge ratio of
800. A total of 2500 shots were carried out for both the
MALDI-TOF and the MALDI-TOF/TOF experiments. To
identify modified proteins, spectra were searched against
the Swiss-Prot database using an in-house version of MAS-
COT [35]. Only those proteins were taken into further con-
sideration that were identified on the basis of at least two
different peptides within one single MS spectrum. Protein
quantification was performed using the Peakpicker software
(Applied Biosystems), which automatically calculates the
relative abundance of light (d0, control) and heavy (d4,
apoptotic) ICPL-labeled peptides as a ratio of light versus
heavy. The d0:d4 ratios determined within one MS spectrum
were averaged and the SD was calculated (see Supplemen-
tary Table 1). The d0:d4 ratio of a protein was considered
significantly altered if the determined averaged value was
greater than twice the SD.
2.10 In vitro phosphorylation
S-20 extracts were prepared from healthy Jurkat cells or Jur-
kat cells treated with CD95-L for the indicated time periods.
Cells were resuspended in hypotonic buffer (10 mM HEPES,
pH 7.5, 5 mM KCl, 1.5 mM MgCl2, 0.1 mM DTT) supple-
mented with 250 mM sucrose. After centrifugation (1646g,
5 min, 47C) the cell pellet was redissolved in hypotonic buffer
without sucrose, kept on ice for 30 min and Dounce homog-
enized to prepare the soluble cytoplasmic and nucleoplasmic
proteins. The in vitro phosphorylation was carried out exactly
as described in Kappes et al. [36].
2.11 In vivo labeling with 32Pi
Labeling of Jurkat cells with 32Pi was performed by washing
cells (16108) three times with phosphate- and serum-free
RPMI medium and then cultivating them in 2 mL of phos-
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phate- and serum-free medium supplemented with 200 mCi
of 32Pi (carrier free; ICN) for the indicated time points. For
induction of apoptosis cells were treated with 2.5% CD95-L-
containing culture supernatant from CD95-L-expressing
N2A cells [30] exactly as described above. Cells were har-
vested by centrifugation (5006g, 5 min) and washed twice
with ice-cold PBS, once with hypotonic buffer (20 mM NaCl,
20 mM HEPES, pH 7.4, 5 mM MgCl2) followed by incuba-
tion in 2 mL hypotonic buffer supplemented with 0.5% NP-
40 and protease (Complete, Roche) and phosphatase inhibi-
tors (NaF, Na-vanadate) for 15 min on ice. After adjusting the
cell suspension to 450 mM NaCl and incubation for further
15 min on ice, insoluble material was pelleted (10006g,
10 min) and the supernatant (whole cell lysate) was used for
immunoprecipitation with DEK specific antibodies. Five
micrograms of affinity purified polyclonal DEK antibody [36]
were used for the equivalent of 16106 cells. After 1 h incu-
bation on ice, 30 mL of a 50% protein A-Sepharose solution
(Amersham Pharmacia) was added and the mixture was rol-
led at 47C for another hour. The immunocomplexes were
washed three times with 1 mL of extraction buffer (450 mM
NaCl, 20 mM HEPES, pH 7.4, 0.5 mM MgCl2) followed by
dissociation from the beads with 2% SDS and 5% b-mercap-
toethanol at 377C for 1 h. The samples were separated by
SDS-PAGE, blotted to NC and analyzed by autoradiography
and immunoblotting.
3 Results and discussion
3.1 A novel combination of cell-free apoptosis and
proteomics
The strategy employed here for the proteomic analysis of
early apoptosis-induced nuclear alterations is outlined in
Fig. 1. Apoptosis was induced in purified mouse liver nuclei
by incubation with cytosolic extracts derived from CD95-L
treated Jurkat cells. Control reactions were performed with
extracts from untreated cells. Subsequently, the nuclei were
recovered from the cell-free reactions and subjected to the
ICPL proteomic platform [22].
The CD95-L triggered apoptotic pathway is very well
characterized [37] and leukemia cells treated with CD95-L
have been used as a source of cytosolic extracts for cell-free
apoptosis reactions in the past (see e.g. [26, 27, 38]). To choose
the time points of cell harvesting to isolate the extracts, we
first analyzed known signal transduction steps triggered by
CD95-L (Fig. 2). The results showed that initiator caspase-8,
the most upstream caspase in this pathway, was already
active at 40 min after treatment, as indicated by the appear-
ance of the p18 active subunit in the corresponding immu-
noblot (Fig. 2A). Within 5 min, caspase-8 processing was
followed by cleavage of Bid, release of cytochrome c, and
partial processing of caspase-3. Caspase 3/7-like activity
(DEVDase) became detectable at 60 min after initial stimu-
lation, followed by the condensation of chromatin at 90 min
Figure 1. Strategy of the cell-free apoptosis/proteomic approach.
Nuclear apoptosis was induced in vitro by combining nuclei iso-
lated from mouse livers with cytosolic extracts derived from Jur-
kat cells stimulated with CD95-L. Control nuclei were incubated
with extracts from untreated cells. The nuclei were recovered
from the cell-free reactions by sedimentation through a small
sucrose gradient and dissolved in a guanidine-containing buffer.
The soluble material was subjected to differential labeling with
the ICPL reagent: proteins of control nuclei were modified with
the light, nondeuterated (d0) form of the reagent, proteins of
apoptotic nuclei with the heavy, deuterated (d4) form. Equal
amounts of each reaction were combined and the mixed sample
separated by 2-DE. After spot excision, proteins were digested in-
gel with trypsin and the resulting material subjected to mass
spectrometric analysis (MALDI-TOF/TOF). Protein identification
was performed by screening against the Swiss-Prot database.
(Fig. 2B). zVAD-fmk efficiently blocked the appearance of
apoptotic signaling intermediates and cell death, confirming
the caspase-dependency of this pathway.
We then verified the ability of extracts isolated at different
time points from CD95-L stimulation to induce distinct
stages of apoptosis in isolated liver nuclei by immunoblot
analysis of two classical caspase targets, PARP-1 and lamin B
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Figure 2. Time-dependent analysis of CD95-L-induced apoptosis
in Jurkat cells. (A) Immunoblot analysis of signaling inter-
mediates. The caspase-3, caspase-8, Bid, and actin blots were
performed with whole cell extracts prepared at the indicated time
points from either untreated or CD95-L treated Jurkat cells. The
cytochrome c blot was performed with lysates obtained from the
same cultures after mild digitonin lysis (see Section 2). To inhibit
caspases, zVAD-fmk was applied at 20 mM, 30 min prior to addi-
tion of CD95-L. p18: active subunit of caspase-8, p17/p19: large
fragment of activated caspase-3, tBid: truncated Bid. (B) Meas-
urement of nuclear condensation and caspase activity in CD95-L
treated Jurkat cell cultures. At the indicated time points, cells
were stained with Hoechst 33342 and examined at the fluores-
cence microscope. For each data point .100 cells were scored in
at least three different microscopic fields. Caspase-3/7-like activi-
ty was determined fluorimetrically by DEVD-afc cleavage. The
data are representative of at least three independent experi-
ments.
(Fig. 3A), by DNA fragmentation analysis (Fig. 3B), and by
microscopic inspection of chromatin structure (Fig. 3C). The
characteristic apoptotic signature fragments of PARP-1
(89 kDa) and lamin B (46 kDa) were barely visible after incu-
bation of the nuclei with extracts obtained at 60 min from
initial stimulation (Fig. 3A), when active caspases were
present at a low level and only a small fraction (20%) of the
population displayed condensed nuclei (Fig. 2A and B). Nei-
ther oligonucleosomal fragmentation nor gross alteration of
chromatin structure were detected in these nuclei (Fig. 3B
and C). By contrast, 120 min-extracts induced substantial
PARP-1 and lamin B cleavage as well as oligonucleosomal
laddering (Fig. 3A and B), consistent with the activation of
apoptotic endonucleases downstream of caspases in the
CD95-mediated apoptosis pathway. Microscopic analysis of
Figure 3. Isolated liver nuclei undergo apoptosis in vitro. (A)
Immunoblot analysis of PARP-1 and lamin B cleavage in nuclei
exposed to cytosolic extracts derived from either untreated (con)
or CD95-L treated Jurkat cells. Extracts were isolated after 60 and
120 min from initial stimulation. (B) Agarose gel electrophoresis
of oligonucleosomal DNA isolated from nuclei treated as in A. (C)
Fluorescence microscopic images of nuclei stained with Hoechst
33342 after recovery from cell-free reactions performed as
described in A (exposure time 10 ms, magnification 636).
these samples revealed loss of chromatin and nucleolar
structures, as well as the induction of peripheral chromatin
condensation (Fig. 3C).
These data demonstrate on the one hand, that the in vitro
system employed here correctly recapitulates the major fea-
tures of nuclear apoptosis. On the other hand, they show that
the system can be exploited to obtain nuclei arrested at dis-
tinct apoptotic stages. Importantly, we did not observe an
increase in caspase activity in the isolated extracts during
cell-free incubations (data not shown) as could potentially
occurr by spontaneous formation of the apoptosome, a cas-
pase-activating multimeric complex [39]. This is most likely
due to the high osmolarity of the buffers used for cell extrac-
tion and for cell-free incubations (110 mM K1 and 70–80 mM
K1, respectively) which was shown to efficiently inhibit
apoptosome formation [40, 41].
Since we were interested in early apoptotic alterations of
the nuclear proteome we wished to isolate cytosolic extracts
from cells committed to, but not yet fully engaged in apop-
totic execution. For the subsequent experiments we therefore
prepared extracts at 30 and 60 min after CD95-L treatment.
The first time point (30 min) was precedent to caspase acti-
vation and apoptotic cell death, whereas at 60 min a minor
fraction of the population displayed an apoptotic morphol-
ogy, as shown above (Fig. 2B).
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Compared to subcellular proteomic approaches based
on the biochemical fractionation of cells undergoing
apoptosis the combination of cell-free apoptosis and pro-
teomics described here has the following distinguishing
features: (i) Subcellular fractionation bears a notoriously
high risk of cross-contamination. In apoptotic cells this is
aggravated by the generation of reactive oxygen species
(ROS) [42] that compromise the stability of intracellular
membranes. Therefore, fractionation protocols established
for healthy cells may not be suited for cells undergoing
apoptosis. Here, isolating nuclei from a healthy tissue
prior to apoptosis induction minimizes the risk of con-
tamination of the nuclei with non-nuclear proteins. (ii)
The components of the cell-free reaction, nuclei and cyto-
sol, can be easily isolated and stored in large quantities.
Therefore, reactions can be repeated from identical start-
ing material keeping variations in sample preparation to a
minimum. (iii) Due to the synchronicity of nuclear apop-
tosis triggered in vitro, homogenous sample material cor-
responding to different stages of the apoptotic process can
be gained using extracts isolated at different time points
from stimulation.
Finally, the reconstituted cell-free apoptosis reaction is
unlikely to sustain de novo gene expression in the absence
of RNAse inhibitors and without the addition of exogenous
precursors. Since caspase-mediate protein cleavage is kept
at a low level by the choice of cytosolic extracts (see above),
alterations of the nuclear proteome in these reactions will
occur predominantly by post-translational events, like pro-
tein modifications and migration in and out of the
nucleus. These events play an important role in the early
cytosol to nucleus signaling phase of apoptosis that we
wished to characterize [43–45]. The ICPL technology in
turn, has been shown to be particularly suited for the
detection of different protein isoforms and protein mod-
ifications since it provides good sequence coverage and
introduces the isotopic label used for quantification at the
protein instead of the peptide level, as e.g., in GIST [22,
46]. Other techniques for quantitative protein profiling, like
SILAC/2-DE, have also been employed in similar studies
with good results [47]. Here, one major advantage was the
shift in pI introduced by the isotopic label, which allowed
to analyze basic nuclear proteins in the neutral region of
the 2-DE (see Section 1). The pI of the proteins is pre-
served also in DIGE, another common quantitative prote-
omic platform, which in addition may encounter problems
in complex protein mixtures when two or more proteins
comigrate [48]. Recently, COFRADIC, a peptide-based pro-
teomic approach, has been successfully applied to the
characterization of apoptosis-induced protein degradation
[49]. While this method proved very powerful for the
detection of protein fragmentation in late apoptotic cells,
its exclusive detection of N-terminal peptides is not suited
for the study of early stages of apoptosis, where the
majority of changes are due to PTMs not necessarily
located at the N-terminus.
In sum, we present here a novel combination of cell-free
apoptosis and the ICPL proteomic platform directed at the
specific detection of early events of nuclear apoptosis, as
induced by death-receptor stimulation.
3.2 Proteome analysis of early apoptotic nuclei
In an initial experiment we first verified whether we would
be able to identify ICPL-modified basic nuclear proteins in
the neutral region of a 2-Dgel taking histone proteins as an
example. Indeed, histone 1.0, which has a calculated pI value
of 10.9 migrated after ICPL-modification below pI 6 (Fig. 4A
upper and lower panel).
Since the control and apoptotic sample were mixed prior
to 2-DE, each ICPL-labeled peptide appeared in the mass
spectrum as a pair of closely spaced peaks corresponding to
the d0 (control, light)- and d4 (apoptotic, heavy) isoform of the
reagent. The mass difference between these peaks amounted
to 4 Da or a multiple of 4 Da depending on the number of
ICPL-modified residues present in the peptide sequence.
This is demonstrated for the RNA-binding protein
hnRNP C in Fig. 4B. Changes in protein abundance due to
the exposure to apoptotic extracts are expressed as the ratio of
the peak intensities in each doublet. In this case, a 60% de-
crease in protein level (ratio d0:d4 = 1:0.44) was detected in
nuclei treated with a 60 min-extract (Fig. 4B, lower panel),
while no significant change was visible when the 30 min-
extract was used (ratio d0:d4 = 1:1.01, Fig. 4B, upper panel).
Peptides showing a change in peak intensities were sub-
jected to MALDI-TOF/TOF for protein identification
(Fig. 4C).
The procedure of cell-free apoptosis/proteomic analysis
described in Fig. 1 was performed three times using differ-
ent preparations of extracts and nuclei. In total, 40 proteins
were found to be differentially regulated (Supplementary
Table 1). Two of them were detected only in nuclei exposed to
30 min-extracts, 25 only in nuclei treated with 60 min-
extracts, and 13 in both type of samples. Two major classes of
proteins emerged from this analysis: chromatin-binding and
RNA-processing factors. The first group included several
histones, the high-mobility group proteins HMGB1 and B2,
the hepatocellular carcinoma protein Hcc-1, hetero-
chromatin-binding protein 1 g (HPl g), and the architectural
chromatin factor DEK. RNA-binding proteins comprised
hnRNPs and splicing factors like U2 snRNPA’, snRNP core
smx5, ASF/SF2, and a protein similar to the splicing factor
arginine/serine-rich (35 kDa). Five candidates, i.e., DEK,
snRNP A’, snRNP core smx5, ribosomal protein S7, and
DEAD-box protein 48 (Ddx 48) have not been implicated in
cell death so far and thus represent potential novel mediators
of nuclear apoptosis.
With few exceptions all proteins were found to be of
murine origin (see Supplementary Table 1) indicating that
nuclei and cytosol could be efficiently separated after the cell-
free reaction and that carry-over of cytosolic components was
minimal. The only human proteins detected were: hnRNP
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Figure 4. Alterations of basic nuclear proteins are detected in the neutral/acidic region of 2-DE after ICPL-modification. (A) 2-DE analysis of
ICPL-modified control nuclei. Nuclei recovered from a cell-free incubation with cytosolic extract from untreated Jurkat cells were chemi-
cally derivatized with the nondeuterated d0 form of the ICPL reagent. Approximately 1 mg of protein was subjected to IEF on pH 3–6 IPG
strips followed by SDS-PAGE as described in Section 2. Protein spots were visualized by silver staining. The arrow indicates the position of
histone H 1.0. The lower panel shows the MALDI-TOF spectrum derived from the indicated spot. (B) MALDI-TOF spectra of a protein spot
containing hnRNP C. The experiment was performed as depicted in Fig. 1. Mouse liver nuclei were incubated with cytosolic extracts from
untreated Jurkat cells and from cells that had been treated either for 30 min or 60 min with CD95-L. After cell-free incubations the nuclei
were mixed in equal amounts. The insets show a blow up of one peak in the region between 1458 and 1480 m/z revealing a doublet of
peptides derivatized either with the d0, nondeuterated or the d4, deuterated form of the ICPL tag. The control samples were labeled with the
d0 form, the apoptotic samples with the d4 form of ICPL. The mass difference of 8 between the two peaks indicates that the peptide contains
two ICPL tags. The ratio of the peak intensities (d0:d4) is unchanged when the control sample was mixed with the 30 min-sample and is
reduced by approximately 60% when the 60 min-extract was used, indicating a reduction in the level of hnRNPC in this sample. (C) MALDI-
TOF/TOF spectrum of the peptide shown B confirms the presence of two lysines modified with the ICPL tag.
H’ and K, Ran, peroxiredoxin I, and ubiquitin. Different
mechanisms and observations may account for this: hnRNP
H’, hnRNP K, and Ran bear nuclear localization sequences
which may support their nuclear entry (see e.g. [50, 51]). Per-
oxiredoxin I/thioredoxin peroxidase-2 is typically located in
the cytosol, but has been recently detected also in the nucleus
of lung cancer cells [52]. Human ubiquitin and the mouse Ubc
protein, the latter identical to polyubiquitin, were recovered
from protein spots migrating in the 2-DE between Mr 15 and
20 kDa. These most likely represent proteins which are mod-
ified with human ubiquitin during the cell-free incubation.
The majority of the identified proteins migrated in the
2-DE as closely spaced spots (Fig. 5). Their position was mostly
shifted only in the horizontal dimension reflecting the pres-
ence of different species of the same protein differing in pI
but not in molecular weight. Some of the neighboring spots
also showed a reciprocal change in the abundance of the
corresponding peptide, possibly indicating conversion of one
protein species into another (see scatter plots for DEK, Hcc-
1, and histone H1.0 in Fig. 5). In general the ratio of iso-
topically light and heavy labeled peptides was moderate
compared to those achieved by changes in gene expression
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Figure 5. Chromatin- and RNA-binding proteins are altered in CD95-mediated apoptosis in vitro. 2-DE analysis of a mixture of control and
apoptotic nuclei labeled with ICPL. Nuclei retrieved from cell-free reactions with cytosolic extracts from untreated and CD95-L treated Jur-
kat cells were chemically derivatized with the nondeuterated d0 and deuterated d4 form of the ICPL reagent, respectively. Approximately
1 mg of protein was subjected to IEF on pH 3–6 IPG strips followed by SDS-PAGE as described in Section 2. Protein spots were visualized by
silver staining and are marked here by lower case letters (a, b, c, etc.). Spots belonging to the same protein, each spot representing a dif-
ferent isoform or modification are encircled by dotted lines. The Figure highlights the staining pattern of 10 out of 40 nuclear proteins
identified as altered during apoptosis. MS-analysis of the spots was performed as exemplified in Fig.4. The results of the MS-analysis are
shown in the scatter plots. Each circle represents the d0:d4 (control:apoptotic) ratio for one protein species as determined in the respective
spot and listed in Supplementary Table 1. Multiple circles belonging to the same spot indicate results obtained from independent 2-D
analyses. Data obtained from experiments performed with 60 min-extracts are indicated by closed circles, open circles show results from
30 min-reactions. Values .1 indicate an increase of the respective protein species in apoptotic nuclei as compared to control nuclei.
[53]. These values, which indicate the relative factor of de-
crease or increase of the corresponding proteins in the
apoptotic sample as compared to control, ranged from 0.28
to 1.96 (see Supplementary Table 1). Collectively these
observations corroborate our assumption that nuclear pro-
tein alterations in the cell-free apoptosis reaction are mainly
arising from post-translational processes rather than from de
novo gene expression.
3.3 Chromatin-binding proteins in nuclear apoptosis
Histone modifications are known to modulate chromatin
architecture and function, and have been associated with
apoptosis both by proteomic and nonproteomic studies (see
Supplementary Table 1). Modifications that have been
observed in different model systems of cellular damage
include dephosphorylation of H1 family histones [54], de-
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ubiquitination of H2A [55], poly(ADP-ribosyl)ation of H1 [56],
biotinylation of H1, H2A, H2B, H3, and H4 [57], hypoacety-
lation of H4 [58], and phosphorylation of H2B [59]. In the
present study, we have identified H1.4 as a further potential
target for apoptosis-specific modification. In general these
modifications are believed to increase the accessibility of
chromatin for apoptotic endonucleases favoring chromatin
condensation, although the exact mechanisms linking his-
tone modification to these processes are not yet understood
[60]. Histones may eventually separate from chromatin and
be released from the nucleus and/or be exposed at the cell
surface as potent autoantigens [61, 62]. In irradiated cells
nuclear release of H1.2 has been shown to function as apop-
totic signal directed at the mitochondria [63].
High-mobility group proteins are DNA-binding factors
affecting chromatin architecture and act in concert with his-
tones in regulating chromatin function [64]. Similarly to his-
tones, their PTMs, in particular methylation, dephos-
phorylation, and poly(ADP-ribosyl)ation have been associated
with apoptosis [65–67]. HMGB2 has further been shown to
activate the apoptotic endonuclease DFF40 in vitro [68]. To our
knowledge, the present study provides the first proteomic data
supporting an involvement of HMGB2 in apoptosis. The dis-
tribution pattern of HMGB2-specific signals on the 2-DE
shows three closely spaced spots, suggestive of PTMs. Whether
these modifications are involved in the ability of HMGB2 to
activate DFF40 remains an open question.
Hcc-1 is a component of the nuclear matrix that is upre-
gulated in a number of tumors and possesses a conserved N-
terminal DNA-binding SAP (SAF A/B, Acinus, Pias) domain
[69, 70]. When expressed in mammalian cells, Hcc-1 exerts
an antiproliferative effect that has been attributed to cell cycle
arrest at the G2/M boundary and more recently to induction
of apoptosis [70]. Interestingly, Hcc-1 has been reported to
interact with two DEAD-box proteins, Bat1 and Ddx39 [70].
These are members of a broad family of RNA-binding
ATPases with helicase activity that are involved in virtually all
cellular processes requiring manipulation of RNA structure
[71]. One member of this family, Ddx48, that has not been
involved in apoptosis so far, has been identified also in our
proteomic screen (Supplementary Table 1).
A further candidate mediator of nuclear apoptosis that
emerged from this study is HP1 g. HP1 is a chromatin-
binding protein that occurs in three isoforms a, b, and g, and
plays a major role in the maintenance and inheritance of
pericentric heterochromatin (reviewed in [72]). All three iso-
forms have been shown to interact with histones, in particu-
lar with histone H3 [73]. This interaction is strongly affected
by post-translational histone modification and was proposed
to mediate binding of HP1 to lamin B receptor (LBR), a
component of the nuclear envelope, providing a mechanism
for the tethering of HP1-enriched heterochromatic domains
to the nuclear envelope [74].
Finally, we identified DEK, a chromatin bound nuclear
phosphoprotein that does not belong to any known protein
family and has not been associated with apoptosis so far. The
only recognizable functional domain is a SAP-box. Proteins
containing this DNA-binding motif participate in chromatin
organization, mRNA processing and transcription, and DEK
was implicated in all these processes (reviewed in [28]). De-
spite these findings the function of DEK remains unclear.
In summary, using an in vitro assay consisting of nuclei
from healthy tissue and early-phase apoptotic extracts we have
identified histones, HMGs and a few other architectural
chromatin proteins, including DEK, as potentially involved in
nuclear apoptosis. These results point to the fact that signals
affecting the topological organization of chromatin are di-
rected to the nucleus already at an early stage of death-recep-
tor triggered apoptosis, preceding the substantial activation of
executor caspases and of DNA cleaving enzymes. This may
represent a general feature of the commitment phase of
apoptotic cell death. In line with these conclusions, Kroemer
and coworkers have shown that a short pulse of staurosporine,
an efficient inducer of apoptosis, induces in moderate altera-
tions of chromatin morphology that do not necessarily result
in cell death. This preapoptotic status was termed PACC, for
preapoptotic chromatin condensation. PACC occurred inde-
pendently of executor caspases and was not associated with
oligonucleosomal DNA fragmentation [75].
3.4 RNA-processing factors involved in nuclear
apoptosis
Rearrangements of ribonucleoprotein-containing compart-
ments leading to the formation of aggregates termed
HERDS (heterogenous ectopic RNP-derived structures) have
been detected during apoptosis by electron microscopy stud-
ies and were shown to accompany the typical apoptotic
changes of chromatin structure [76–78]. Among the RNPs
identified in HERDS are pre-mRNA-binding RNPs,
hnRNPs, and small nuclear RNPs, snRNPs, as well as other,
non-snRNP splicing factors [77]. In addition to these mor-
phological data, alterations of hnRNPs have been reported
also by proteome studies in different models of cell death
(see Supplementary Table 1). HnRNPA2/B1, a shuttling
hnRNP, was found to accumulate in the cytoplasm of CD95-
L treated Jurkat cells [18], corroborating our own results
which show a consistent reduction of the hnRNPA2/B1 level
in nuclei incubated with apoptotic cytosol (Fig. 5). This effect
is among the few ones that we repeatedly observed in nuclei
incubated with 30 min-extracts, i.e., in absence of active cas-
pases, suggesting that alterations of hnRNPA2/B1 traffick-
ing is among the very early nuclear events in CD95-L-
induced apoptosis. We also detected a decrease of nuclear
levels of hnRNP C1/C2, a nonshuttling hnRNP [79]. This
hnRNP has been identified early on as a caspase substrate
[80]. Proteolytic cleavage may partly account for the loss of
hnRNP C1/C2 from liver nuclei in the cell-free apoptosis
reaction, but is not likely to play a major role, given the low
level of active caspases in this system. More importantly, a
caspase-independent mechanism of nuclear efflux of hnRNP
C1/C2 has been recently described which does not involve
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proteolytic cleavage but the activation of a novel nuclear
export signal located at the C-terminus of the protein by Rho-
associated kinase [81].
Our study further revealed a reduction in the level of
hnRNP H’, hnRNP K, and hnRNP I. Little is known about
the physiological significance of the involvement of hnRNPs
in apoptosis. hnRNP F and H have been shown to modulate
the alternative splicing of Bcl-x pre-mRNA [82] and several
hnRNPs have been identified in proteomic studies of apop-
totic cells (see Supplementary Table 1). This supports the
assumption that alterations of hnRNP nucleo-cytoplasmic
distribution and/or their PTMs may indeed have a functional
significance in apoptosis.
Among the RNPs identified in this study are also splicing
factors like the snRNP core protein Smx5, the U2 snRNP
A’and ASF/SF2. While the molecular alterations occurring in
this system remain to be determined, it is known from liter-
ature that modification of splicing factors by phosphoryla-
tion regulate protein–protein and protein–RNA interactions
within the spliceosome. This may influence the progression
of the splicing reaction and the choice of the splice-site in
alternative splicing (reviewed in [83]). The induction of
changes in the levels of specific splicing factors during
exposure of nuclei to apoptotic extracts may reflect an early
reprogramming of splicing reactions as part of the commit-
ment phase of apoptosis. In fact, many members of the
apoptosis pathway were shown to be regulated by alternative
splicing. These include the genes encoding Bcl-2 family
members, several caspases, Apaf-1, the endonuclease
DFF40/CAD, and CD95 (reviewed in [84]).
Finally, our data point to an early involvement of the
nucleolus in the CD95-dependent signal pathway. Two com-
ponents of the 40 S ribosomal subunit were found to be
altered in preapoptotic nuclei, S3A and S7. Also nucleo-
phosmin, an abundant nucleolar phosphoprotein involved in
ribosomal biogenesis was identified as a target of CD95-
induced apoptosis. Several lines of evidence support a role of
nucleophosmin as an antiapoptotic survival protein [85, 86].
More recently, nucleophosmin has been shown to mediate
the antiapoptotic effects of NGF by binding and inhibiting
the apoptotic DNAse DFF40/CAD in the presence of phos-
phatidylinositol 3,4,5-triphosphate [87]. This function of
nucleophosmin was proposed to be regulated by PTM, in
particular by phosphorylation. The identification of nucleo-
phosmin in our study suggests that the regulation of the
nucleophosmin–CAD interaction by phosphorylation may
represent also a novel regulatory component of death recep-
tor-mediated apoptosis.
3.5 DEK is hypophosphorylated in apoptotic nuclei
One of the proteins identified in this study for which a link to
apoptosis had not been established so far is the chromatin
architectural factor DEK. The DEK protein was initially
identified as an oncogenic fusion with the nucleoporin CAN/
Nup214 in patients suffering from acute myeloid leukemia
[88]. An increased level of DEK mRNA in many cancerous
cells has been reported suggesting that DEK may play a role
in cellular transformation and senescence [89–95]. In addi-
tion, DEK has been shown to be a major antigen in several
autoimmune disorders [96]. However, the biological function
of DEK and the molecular mechanisms by which it con-
tributes to disease pathogenesis have not been clarified yet.
DEK is an abundant nuclear phosphoprotein [97] that is
tightly associated with chromatin throughout the cell cycle
[98]. In vitro, DEK was shown to modify chromatin topology
by introducing constrained positive supercoils in closed cir-
cular DNA templates, an activity which requires topoisome-
rase I [99, 100]. The structural features of DEK have been
reviewed recently and a model for the interaction of DEK
with DNA has been proposed [28]. This model takes into
account the observation that DEK’s binding to DNA as well
as its ability to form multimers are modulated by phospho-
rylation, mainly by the protein kinase CK2. Increasing the
level of phosphorylation reduces the affinity of DEK for DNA
and augments its tendency to form aggregates [36, 101].
In the 2-DE of the ICPL-labeled nuclear samples DEK
was identified in two protein spots migrating at slightly dif-
ferent pI- but identical Mr-values, which was indicative of the
occurrence of two differentially modified species of the pro-
tein. The determination of the ratio of light (d0, control) to
heavy (d4, apoptotic) isomer in both spots showed that in the
apoptotic sample the more basic DEK-variant (spot a) was
increased, while the more acidic (spot b) was decreased
(Fig. 6A). Considering that DEK is a known target for phos-
phorylation in vivo and in vitro, these data potentially indi-
cated a change in the phosphorylation status of DEK in liver
nuclei during the cell-free apoptosis reaction. To confirm this
we compared the ability of extracts gained from untreated
and apoptotic Jurkat cells to phosphorylate recombinant His-
tagged DEK under conditions identical to those employed for
the cell-free apoptosis reaction. As shown in Fig. 6B extracts
from healthy Jurkat cells induced a robust phosphorylation
of DEK in vitro, in accordance to previous results with HeLa
cell extracts [36]. A progressive decrease in the level of DEK
phosphorylation was observed with extracts derived from
Jurkat cells treated for different times with CD95-L, in line
with our results from the proteome analysis of liver nuclei.
Since this experiment was performed in the presence of
phosphatase inhibitors, the decrease in phosphorylation is
most likely due to a reduced kinase activity in the corre-
sponding extracts and not to the induction of a DEK-specific
phosphatase in the course of apoptosis. Finally, we were
interested to determine whether a change in the level of DEK
phosphorylation would also occur in intact cells undergoing
apoptosis. For this purpose Jurkat cells were labeled with 32P-
orthophosphate and incubated for different times in the
presence or absence of CD95-L. Cleavage of PARP-1 occur-
red specifically and in a time-dependent manner in the
CD95-L treated cultures as shown by immunoblot analysis
(Fig. 6C). No degradation of DEK could be detected in these
cultures (Fig. 6C). Autoradiography of immunoprecipitated
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Figure 6. DEK is hypophosphorylated in apoptosis in vitro and in vivo. (A) zoomed area of the 2-D gel of Fig. 5 highlighting the DEK-specific
spots. The scatter plot shows the results of the quantitation as described in the legend to Fig. 5 and Section 2. In the apoptotic sample the
DEK-specific signal from spot (a) is increased, while spot (b) decreases, suggesting a PTM of the protein. (B) In vitro phosphorylation.
Recombinant, dephosphorylated His-tagged DEK (500 ng) was incubated with equal amounts (150 mg total protein) of S-20 extract,
obtained from untreated (con) or from Jurkat cells treated for the indicated time points with CD95-L (30, 60, and 120 min) and in the pres-
ence of g-32P-ATP. Reactions were stopped immediately (0 min) or after 5 min, and DEK was purified using Ni-NTA-agarose. The individual
eluates were analyzed by immunoblotting (a-DEK) and autoradiography (32P). (C) In vivo labeling of control and CD95-L treated Jurkat cells.
Jurkat cells were collected and incubated in the presence of 32Pi either with or without 2.5% of CD95-L. At the indicated time points a total
cell lysate was produced and analyzed in immunoblots with PARP-1, ORC-2 and DEK specific antibodies. (D) The same extracts were treated
with polyclonal DEK specific antibodies and the eluted immunocomplexes were analyzed by autoradiography (32P) and immunoblotting
with a monoclonal DEK antibody (a-DEK, BD Bioscience). (E) For densitometric analysis, bands were scanned and analyzed by NIH Imager.
The ratio of the autoradiograph versus the immunoblot is visualized.
DEK from the same experiment as in Fig. 6C indicated a
lower level of DEK phosphorylation in the lysates obtained
from cells undergoing apoptosis as compared to control
lysates (compare immunoblot signals with autoradiography,
Fig. 6E). This appeared most clearly at 3 h after treatment
(Fig. 6D and E, compare lane 4 with lane 7). ORC-2, a com-
ponent of the origin recognition complex, was unaffected in
this experiment and served as a loading control (Fig. 6C).
At present, the significance of DEK hypophosphorylation
in apoptosis is unclear. A lower level of DEK phosphorylation
however, is expected to enhance its DNA binding activity. This
in turn may contribute to keep DEK fixed to chromatin during
the process of nuclear destruction and apoptotic body forma-
tion avoiding a potentially harmful release of the protein to the
cytoplasm and the extracellular space. Failure of the nuclear
retention of DEK may be relevant for its role as autoantigen. A
similar scenario has been shown to apply for HMGB1, which
can act as a potent proinflammatory stimulus when released
by necrotic cells. In apoptotic cells, HMGB1 is irreversibly
locked to chromatin as a consequence of histone hypoacety-
lation [58]. As a further possibility, hypophosphorylated DEK
may facilitate chromatin compaction by bridging between
distant binding sites on the same or on different DNA strands
via its two DNA-binding domains, as proposed by the model of
Waldmann et al. [28]. Third, DEK hypophosphorylation in
apoptosis may impinge on its postulated functions in splicing
and transcription. In fact, dephosphorylation of DEK has been
shown to relieve transcriptional repression of the human
immunodeficiency Virus type 2 (HIV-2) promoter [102] in
mitogenically stimulated leukemia cells.
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In summary we have shown that the DEK protein is
hypophosphorylated in apoptosis induced in vitro and in vivo.
This validates our results from the proteomic analysis of
nuclear apoptosis and highlights the potential of this
approach for the investigation of apoptosis-induced PTMs.
Furthermore, our results establish a previously unrecognized
link between DEK and cell death, which will prove useful in
the search for the physiological function of this protein.
4 Concluding remarks
Cell death by apoptosis is characterized by dramatic altera-
tions of nuclear morphology and chromatin architecture.
These are brought about mainly by the action of the caspase
family of proteases, by apoptosis-specific endonucleases, and
chromatin condensation factors. We have performed a pro-
teomic screen of apoptotic nuclei using a combination of
cell-free apoptosis and ICPL. Interestingly, part of the pro-
teins identified in this study have emerged also from pre-
vious proteomic studies of apoptotic cells using different
apoptotic stimuli, fractionation techniques, and proteomic
platforms (for a complete reference list, see Supplementary
Table 1). While, on the one hand, this corroborates the sig-
nificance of our data, on the other hand it shows that differ-
ent strategies of proteomic analysis, each bearing different
merits and disadvantages, may complement each other and
collectively contribute to characterize apoptosis-induced
alterations of the cellular proteome (see e.g. [48]). Since ICPL
is a rather new platform, only very few reports using this
technique are available at present. More studies are to be
awaited in the future and will allow for accurate cross-
comparison of this method with other quantitative protein
profiling tools.
The study described here was aimed specifically at dis-
playing changes of the protein complement of the nucleus
triggered at an early phase of cell death. The identification of
chromatin architectural proteins and RNA-processing fac-
tors in our screen suggests that initial steps of apoptotic sig-
naling may occur in the nucleus prior to the full activation of
the cytoplasmic caspase cascade. These steps may involve
PTMs of nuclear proteins, as exemplified for the protein
DEK. Assessing the role of the identified candidates and
particularly of the hypophosphorylation of DEK, in the pro-
cess of apoptotic cell death is a challenging endeavor for the
future.
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